Three investigational treatments for Huntington’s disease, non-small cell lung cancer and Alzheimer’s disease have received Innovation Passports through the UK’s Innovative Licensing and Access Pathway (ILAP).
The Medicines and Healthcare products Regulatory Agency (MHRA) has awarded Innovation Passports to three investigational medicines targeting areas of significant unmet clinical need, allowing their developers to access coordinated support from the regulator, NHS and health technology assessment (HTA) bodies through the UK’s Innovative Licensing and Access Pathway (ILAP).
The treatments include a small interfering RNA (siRNA) therapy for Huntington’s disease, a small-molecule oncology therapy targeting non-small cell lung cancer (NSCLC), and an antisense oligonucleotide (ASO) for early Alzheimer’s disease.
The three medicines are Alnylam’s brezosiran, BeOne Medicines’ BGB-58067 and Biogen’s diranersen, respectively.
The Innovation Passports were awarded following assessment by the ILAP Selection Panel. The pathway aims to reduce development risks and support earlier patient access by providing a platform for collaboration between medicine developers and partners across the UK health system.
Professor Jacob George, Chief Medical and Scientific Officer at the MHRA, said: “The Innovative Licensing and Access Pathway is a globally unique initiative designed to accelerate patient access to transformative new medicines and drug-device combinations.”
John Spoors, Deputy Director of Medicines Evaluation at NICE, added: “NICE welcomes the opportunity, through ILAP, to work with developers and partners across the health system to support evidence generation and early engagement on the issues that will shape future evaluation and patient access.”
The three medicines remain investigational, and any future availability will depend on evidence demonstrating their safety, effectiveness and value.
The next round of Innovation Passport applications opened today (9 November 2026) and will remain open until 11 February 2027.
No comments yet